Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Size By Type (Pcr, In Situ Hybridization), By Application (Hospital, Research), By Region, And Segmen...

The Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market was valued at USD 1.35 billion in 2023 and is projected to surpass USD 2.62 billion by 2031, growing at a CAGR of 8.8% during the forecast period from 2023 to 2031. The growth is primarily driven by increasing incidence of sexually transmitted infections (STIs), rising awareness and government initiatives toward STI prevention, and technological advancements in molecular diagnostic tools offering rapid, accurate, and point-of-care testing.

Molecular diagnostics have become the gold standard for CT/NG detection due to their superior sensitivity and specificity compared to traditional culture or serological tests. Integration of automation, miniaturization, and digital connectivity in diagnostic platforms is further accelerating market adoption across hospital labs, clinics, and diagnostic centers.

Drivers:

Rising Prevalence of STIs:

A surge in global Chlamydia and Gonorrhea infections, particularly among adolescents and young adults, is increasing the need for early, reliable diagnostics to prevent complications such as infertility and pelvic inflammatory disease.

Shift Toward Molecular Diagnostics:

The transition from conventional methods to nucleic acid amplification tests (NAATs) is a major market driver, owing to higher diagnostic accuracy, shorter turnaround times, and ease of use in various healthcare settings.

Government Screening Programs:

Public health screening initiatives across North America, Europe, and Asia-Pacific are promoting widespread CT/NG testing, especially in high-risk populations, supporting equipment demand.

Restraints:

High Cost of Molecular Diagnostic Systems:

Advanced diagnostic systems involve significant upfront and maintenance costs, limiting adoption in low-resource settings.

Limited Awareness in Developing Regions:

In certain low- and middle-income countries, limited awareness about CT/NG infections and low testing rates pose a challenge to market expansion.

Opportunity:

Rising Demand for Point-of-Care (POC) Molecular Testing:

The growing preference for decentralized testing environments is boosting demand for portable, user-friendly diagnostic equipment that delivers rapid results without compromising accuracy.

Technological Innovation in Sample-to-Answer Systems:

Next-gen automated platforms with multiplexing capabilities and minimal hands-on time are expected to drive strong growth in the diagnostic space.

Market by System Type Insights:

The NAAT-based Diagnostic Systems segment dominated the market in 2023, accounting for over 70% of the total revenue. These systems are widely preferred for their exceptional sensitivity and specificity in detecting CT/NG DNA or RNA from various clinical samples, including urine, vaginal swabs, and endocervical swabs. The segment is expected to maintain its dominance through 2031, propelled by the launch of compact, integrated sample-to-answer platforms suitable for near-patient and POC applications.

Market by End-Use Insights:

In terms of end use, Diagnostic Laboratories emerged as the leading segment in 2023, holding more than 45% market share. These laboratories routinely perform high-volume testing using molecular platforms and play a crucial role in national screening programs. Meanwhile, Clinics and Physician Offices are expected to witness the highest growth during the forecast period, driven by the availability of rapid molecular testing systems tailored for decentralized care settings.

Market by Regional Insights:

North America held the largest share in 2023, supported by robust healthcare infrastructure, high STI awareness, and government-led screening programs. The Asia-Pacific region is poised for the fastest growth over the forecast period, attributed to rising STI prevalence, increasing healthcare investments, and expansion of POC diagnostics across emerging economies such as India and China.

Competitive Scenario:

Key players in the Global Molecular CT/NG Diagnostic Equipment Market include:

Hologic, Inc.

Roche Diagnostics

Abbott Laboratories

Cepheid (a Danaher Company)

BD (Becton, Dickinson and Company)

QuidelOrtho Corporation

BioMérieux SA

Thermo Fisher Scientific

These companies are engaged in strategic product launches, collaborations, and expansion of diagnostic portfolios tailored for rapid and accurate CT/NG testing. For instance:

In 2023, Cepheid expanded its Xpert Xpress CT/NG assay distribution across primary care clinics in the U.S.

In 2024, Roche Diagnostics received regulatory approval for its cobas CT/NG test on the cobas 5800 system, extending its molecular platform coverage for smaller labs.

Abbott launched its rapid molecular ID NOW CT/NG test in early 2025, focusing on POC testing in urgent care settings.

Scope of Work – Global Molecular CT/NG Diagnostic Equipment Market

Report Metric Details

Market Size (2023) USD 1.35 Billion

Projected Market Size (2031) USD 2.62 Billion

CAGR (2023–2031) 8.8%

Market Segments System Type (NAAT, Others); End Use (Labs, Clinics, Hospitals); Region

Growth Drivers STI prevalence, shift to molecular diagnostics, government screening

Opportunities Point-of-care diagnostics, automated sample-to-answer platforms

Key Market Developments:

Jan 2023: BD launched a multiplex assay enabling simultaneous CT/NG detection and antibiotic resistance profiling.

Aug 2024: Hologic introduced an upgraded Panther system offering improved throughput and turnaround time.

Mar 2025: BioMérieux collaborated with a national health program in Europe to deploy rapid CT/NG testing at the community level.

FAQs:

1) What is the current market size of the Global Molecular CT/NG Diagnostic Equipment Market?

The market was valued at USD 1.35 billion in 2023.

2) What is the major growth driver of the Global Molecular CT/NG Diagnostic Equipment Market?

The increasing prevalence of STIs and the shift toward highly accurate molecular diagnostic tools are major drivers.

3) Which is the largest region during the forecast period in the Global Molecular CT/NG Diagnostic Equipment Market?

North America leads the market due to strong healthcare infrastructure and robust screening initiatives.

4) Which segment accounted for the largest market share in Global Molecular CT/NG Diagnostic Equipment Market?

The NAAT-based Diagnostic Systems segment held the largest share in 2023.

5) Who are the key market players in the Global Molecular CT/NG Diagnostic Equipment Market?

Leading players include Hologic, Roche Diagnostics, Abbott, Cepheid, BD, and QuidelOrtho Corporation.